Spero Therapeutics Inc (NASDAQ:SPRO) has been given a consensus recommendation of “Hold” by the six research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $28.00.
Several equities research analysts have recently issued reports on the company. Bank of America assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating for the company. Stifel Nicolaus assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 price objective for the company. Cowen assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating for the company. Oppenheimer assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, ValuEngine raised Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday.
Spero Therapeutics (SPRO) traded down $0.19 during midday trading on Friday, reaching $11.90. The company’s stock had a trading volume of 7,233 shares, compared to its average volume of 28,314. The stock has a market cap of $172.43 and a PE ratio of -4.21. Spero Therapeutics has a fifty-two week low of $9.84 and a fifty-two week high of $15.40.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share for the quarter, missing the consensus estimate of ($2.43) by ($33.59). The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $0.20 million. equities analysts forecast that Spero Therapeutics will post -8.52 EPS for the current fiscal year.
An institutional investor recently bought a new position in Spero Therapeutics stock. Dean Capital Investments Management LLC acquired a new stake in Spero Therapeutics Inc (NASDAQ:SPRO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,039 shares of the company’s stock, valued at approximately $118,000. Dean Capital Investments Management LLC owned about 0.07% of Spero Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 0.01% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set Spero Therapeutics Inc (SPRO) PT at $28.00” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/05/brokerages-set-spero-therapeutics-inc-spro-pt-at-28-00.html.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.